Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eunhye Jeon"'
Autor:
Namkyoung Kim, Injae Shin, Younghoon Kim, Eunhye Jeon, Jiwon Lee, Chaeyoung Lee, Yunju Nam, Sumin Lee, Eunhye Ju, Chan Kim, Woolim Son, SeongShick Ryu, Minjoo Ko, Taebo Sim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
RAS mutants are involved in approximately 30% of all human cancers and have been regarded as undruggable targets owing to relatively smooth protein surface and obscure binding pockets. In our previous study, we have demonstrated that GNF-7, a multi-t
Externí odkaz:
https://doaj.org/article/ab077dce29e646abaf028b086d8ff2d9
Autor:
Younghoon Kim, Christina Seo, Eunhye Jeon, Inchul You, Kyubin Hwang, Namkyoung Kim, Ha-Soon Choi, Stephen M. Hinshaw, Nathanael S. Gray, Taebo Sim
Chemically induced protein degradation is a powerful strategy for perturbing cellular biochemistry. The predominant mechanism of action for protein degrader drugs involves induced proximity between the cellular ubiquitin conjugation machinery and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b0d1e8e364fb54308433ab122b67db
https://doi.org/10.1101/2022.12.17.520883
https://doi.org/10.1101/2022.12.17.520883
Autor:
Chiman Song, SeongShick Ryu, Nam Doo Kim, Nam Hoon Kwon, Taebo Sim, Injae Shin, Eunhye Jeon, Ji Won Lee, Youngji Moon, Young Hoon Kim, Hojong Yoon, Sunghoon Kim, Hwan Geun Choi, Hanna Cho
Publikováno v:
Journal of Medicinal Chemistry. 64:11934-11957
Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2-d]pyrimidine derivatives. An intensive structure-activity relationship (SAR) stud
Autor:
SeongShick Ryu, Yunju Nam, Namkyoung Kim, Injae Shin, Eunhye Jeon, Younghoon Kim, Nam Doo Kim, Taebo Sim
Publikováno v:
Journal of medicinal chemistry. 65(8)
Although FGFR inhibitors hold promise in treating various cancers, resistance to the FGFR inhibitors caused by acquired secondary mutations has emerged. To discover novel FGFR inhibitors capable of inhibiting FGFR mutations, including gatekeeper muta
Publikováno v:
Microbiology resource announcements. 11(4)
Stenotrophomonas maltophilia is a multidrug-resistant nosocomial pathogen that can cause life-threatening infections among immunocompromised populations. This report presents the complete 74,962-bp genome of S. maltophilia podophage Paxi, an N4-like
Publikováno v:
Aqua, Vol 73, Iss 5, Pp 969-979 (2024)
This study introduces an innovative diagnostic approach for identifying gate-valve failures in water distribution systems. By implementing high-frequency pressure sensors upstream and downstream of the gate valves, we obtained detailed pressure data
Externí odkaz:
https://doaj.org/article/1ab709058dce409ca798dfff35b5a0f1
Autor:
Hanna, Cho, Injae, Shin, Hojong, Yoon, Eunhye, Jeon, Jiwon, Lee, Younghoon, Kim, SeongShick, Ryu, Chiman, Song, Nam Hoon, Kwon, Youngji, Moon, Sunghoon, Kim, Nam Doo, Kim, Hwan Geun, Choi, Taebo, Sim
Publikováno v:
Journal of medicinal chemistry. 64(16)
Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2
Autor:
Gracelyn King, Spencer Keith, Rebecca Philip, Christopher M. Quick, Eunhye Jeon, Cayla Jenkins
Publikováno v:
The FASEB Journal. 35
Autor:
Eunhye Ju, Injae Shin, Eunhye Jeon, SeongShick Ryu, Wonjeong Cho, Namkyoung Kim, Ji Won Lee, Taebo Sim, Young Hoon Kim
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 7
International Journal of Molecular Sciences, Vol 22, Iss 3783, p 3783 (2021)
Volume 22
Issue 7
International Journal of Molecular Sciences, Vol 22, Iss 3783, p 3783 (2021)
Melanoma accounts for the majority of skin cancer deaths. About 50% of all melanomas are associated with BRAF mutations. BRAF mutations are classified into three classes with regard to dependency on RAF dimerization and RAS signaling. The most freque
Autor:
Eunhye Jeon, Chan-Goo Yi
Publikováno v:
Journal of Social Science. 29:85-109